WeVote
Log In

Bill

Bill

LD 1687

An Act To Clarify And Increase Access To Hiv Prevention Medications

132nd Legislature (2025-2026) Introduced by Michelle Boyer and 4 co-sponsors

Authorizes Maine pharmacists to prescribe, dispense, and administer HIV prevention meds (PrEP/PEP) with MaineCare reimbursement, up to 60-day supply every 2 years, starting 1/1/2027.

Signed by Governor
#healthcarepersonnel #hivpreventionmeds #pharmacists
0
WeVote Research Nonpartisan
Bill Summary · LD 1687

Summary — LD 1687: An Act To Clarify And Increase Access To HIV Prevention Medications

Status: Signed by Governor (July 1, 2025)
Introduced: April 17, 2025
Committee: Health Coverage, Insurance and Financial Services
Final action: Passed to be enacted (June 11–25, 2025); amended by Committee Amendment "A" (H‑642)

Purpose

To clarify and increase access to HIV prevention medications by allowing pharmacists to prescribe, dispense and administer those medications and by establishing reimbursement under MaineCare for those pharmacist services.

(“HIV prevention medications” commonly include drugs used for PrEP and PEP; the bill text and fiscal note refer generally to HIV prevention medications.)

Key provisions

  • Authorizes pharmacists to prescribe, dispense and administer HIV prevention medications (as defined in the bill).
  • Requires MaineCare to reimburse pharmacists for providing these services.
  • Reimbursement limit: an amount not to exceed a 60‑day supply to an individual once every two years.
  • Sets an implementation date for MaineCare reimbursement: January 1, 2027 (per the fiscal note).
  • Directs agencies to implement rules and administrative changes as needed; any implementation costs to the Maine Board of Pharmacy are expected to be minor and absorbable within existing resources.

Fiscal impact (summary from fiscal note)

  • FY 2026‑27 net General Fund cost: $44,264 (includes one‑time and ongoing items).
    • One‑time General Fund appropriation (technology costs to implement MaineCare reimbursement): $42,974 in FY 2026‑27.
    • Ongoing General Fund appropriation for pharmacist reimbursement: $1,474 beginning in FY 2026‑27.
  • FY 2027‑28 and FY 2028‑29 General Fund net cost: $2,939 each year.
  • Federal Expenditures Fund (matching funds) and Other Special Revenue Funds (drug rebate offsets) are included in the projection:
    • FY 2026‑27: Federal funds $146,951; Other special revenue $1,609.
    • FY 2027‑28 and FY 2028‑29: Federal funds $31,183 each year; Other special revenue $3,218 each year.
  • The Maine Board of Pharmacy is expected to absorb any minor additional administrative costs within existing budgets.

Who is affected

  • Pharmacists: permitted to provide and be reimbursed for prescribing/dispensing/administering HIV prevention medications under MaineCare.
  • MaineCare beneficiaries: increased point‑of‑care access to HIV prevention medications through participating pharmacists.
  • Department of Health and Human Services: implements reimbursement policy and systems changes; receives appropriations.
  • Department of Professional and Financial Regulation, Maine Board of Pharmacy: minimal administrative impact.

Implementation and timeline

  • MaineCare reimbursement for pharmacist services is scheduled to begin January 1, 2027 (per fiscal note).
  • One‑time technology implementation funds provided in FY 2026‑27 to support system changes.

Legislative actions (select)

  • Committee Amendment "A" (H‑642) adopted; bill passed to be engrossed and enacted in June 2025.
  • Signed by Governor on July 1, 2025.

This summary is based on the bill title, legislative history, and the fiscal notes for LD 1687 (as engrossed with Committee Amendment A).

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.